BUSINESS
J&J starts reimbursement programme for Indian patients with faulty ASR hip implants
The reimbursement programme called as ASR India Patient Assistance Programme (IPAP) will support patients who have been implanted in India with its ASR hip implant from June 2004 to August 2010 and provide reimbursement, if the revision surgery and the tests have taken place within 15 years from the date of the primary hip replacement surgery.
BUSINESS
Kilitch Drugs bets on Africa to grow sales in its comeback bid
The company is targeting to double the sales in the current financial year, and is well on the track to achieve it.
BUSINESS
L&T sticks to FY19 guidance, expects additional govt orders before 2019 general elections
L&T said growth in order inflow was primarily led by government and public sector undertakings, while the private sector investment continues to remain subdued
BUSINESS
Lupin promises better show in H2FY19 on US price stability, new launches
The company said it sees the pricing erosion in US settle down at single digit from double digit in the previous quarters.
BUSINESS
Centre in no hurry to revise PMJAY package rates, private hospitals will have to wait
PMJAY or Ayushman Bharat, popularly known as ModiCare, aims to provide Rs 5 lakh coverage to 10 crore poor families or nearly half a billion people and is considered an important scheme politically for Narendra Modi to showcase to voters as he heads for the general elections next year.
BUSINESS
CCI approves IHH Healthcare's Rs 4,000 crore acquisition of Fortis
With the CCI approval, IHH will be able to make an open offer for an additional 26 percent stake.
BUSINESS
Indian API makers expect rise in order inflows amid price hikes, supply disruption in China
Moneycontrol reported in August that some drug makers are working towards producing APIs and key starting materials in house, while others have started qualifying Indian sources for procurement.
BUSINESS
Dr Reddy's gets 8 USFDA observations for Duvvada injectable site
The company's Duvvada unit, known as FTO-VII, manufactures cytotoxic and hormonal injectables is under warning since November 2015, blocking any new approvals.
BUSINESS
Competition Commission's policy prescriptions to make healthcare transparent, affordable
CCI, which has so far received 52 cases pertaining to anti-competitive practices in pharmaceutical and healthcare sector, prescribed some policy and regulatory action to address issues choking competition.
BUSINESS
Biocon confident of meeting $200-million revenue guidance target for biologics segment
“We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.
BUSINESS
Dr Reddy’s says focusing on resolving regulatory issues, cost optimisation
“Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will enable affordable medicines for more patients,” GV Prasad, Co-chairman and CEO of Dr Reddy’s said.
BUSINESS
Re-audit of Duvvada unit: Why an all clear holds importance for Dr Reddy’s
A portion of complex abbreviated new drug applications is filed from this facility
BUSINESS
Modi govt destroying institutions like CBI: Andhra Pradesh CM Chandrababu Naidu
The TDP supremo evaded questions on efforts to bring the Opposition together
BUSINESS
Patients with faulty J&J hip implants say no word from govt so far on compensation
Although J&J has been criticized for failing to pay any compensation for its faulty hip implant in India, there are currently no legal provisions to provide compensation to affected patients
BUSINESS
Weekly blog: More questions, no definitive answers on source of polio vaccine contamination
Bio Farma told Moneycontrol that it had conducted an internal investigation of the facility and that testing of retained samples of all bulks shipped to Bio-Med had found no of presence of a type 2 polio virus
BUSINESS
Biocon inches closer for Europe approval of biosimilar Trastuzumab
Trastuzumab, the biosimilar version of Swiss drug maker Roche’s Herceptin had brand sales of $1.9 billion in Europe for the 12 months ended July 31, according to IQVIA.
BUSINESS
Lupin gets 5 observations from USFDA for Pithampur Unit-3 facility
The pre-approval inspection (PAI) was triggered after the company filed Tiotropium dry powder inhalation (DPI) abbreivated new drug application (ANDA).
BUSINESS
Exclusive: As polio threat looms, Indonesia's Bio Farma denies contamination of oral vaccine
Bio Farma has come under the lens of Indian drug regulator CDSCO as it supplied bulk vaccine or key starting material to Biomed.
BUSINESS
Will Dr Reddy's biosimilar programme for developed markets see traction?
The drug maker's partner Fresenius Kabi has completed clinical trial for Pegfilgrastim and announced that the drug has met primary end point in two pivotal clinical studies.
BUSINESS
Bio-Med polio episode underlines the story of India's famed vaccine industry losing prowess
India, once the manufacturing powerhouse of vaccines, is seeing a slow decline. India’s vaccines exports dropped 4 percent to $653.40 million in FY18
BUSINESS
Sacked IL&FS MD blames LIC, macro factors for mess, denies fund diversion charges
Sankaran asked NCLT to appoint an independent foreign agency without conflict of interest, rather than a local one, to investigate the company's affairs
BUSINESS
Piramal considers $1-billion pharma services business sale: Reports
But analysts say pharma services constitute 6-7 percent of Piramal's revenues and is a drag on overall pharma business.
BUSINESS
E-pharmacy definition outdated, changes should be made to attract FDI, says IAMAI
The Union Health Ministry recently released draft rules for e-pharmacies to regulate online sale of medicines across the country and provide patients accessibility to genuine drugs.
BUSINESS
Dr Reddy's on cost cutting spree to counter US pricing pressures
The company has been selling manufacturing plants, optimizing product portfolios, removing layers of management that it considers wasteful and taking re-look at R&D investments.
